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Abstract
Background: Many studies have been published outlining the global effects of 17b-estradiol (E2) on gene
expression in human epithelial breast cancer derived MCF-7 cells. These studies show large variation in results,
reporting between ~100 and ~1500 genes regulated by E2, with poor overlap.
Results: We performed a meta-analysis of these expression studies, using the Rank product method to obtain a
more accurate and stable list of the differentially expressed genes, and of pathways regulated by E2. We analyzed
9 time-series data sets, concentrating on response at 3-4 hrs (early) and at 24 hrs (late). We found >1000
statistically significant probe sets after correction for multiple testing at 3-4 hrs, and >2000 significant probe sets at
24 hrs. Differentially expressed genes were examined by pathway analysis. This revealed 15 early response
pathways, mostly related to cell signaling and proliferation, and 20 late response pathways, mostly related to breast
cancer, cell division, DNA repair and recombination.
Conclusions: Our results confirm that meta-analysis identified more differentially expressed genes than the
individual studies, and that these genes act together in networks. These results provide new insight into E2
regulated mechanisms, especially in the context of breast cancer.
Keywords: microarray, meta-analysis, estrogen, breast cancer, pathways
Background
Estrogens are fundamental to the function of the female
reproductive system, and have also been shown to regu-
late diverse cellular processes in the central nervous sys-
tem, the cardiovascular system, and bone metabolism
[1]. Estrogens play a key role in proliferation and differ-
entiation of healthy breast epithelium, but also contri-
bute to the progression of breast cancer by promoting
the growth of transformed cells [2]. The predominant
effect of estrogen is mediated through its interaction
with two intracellular estrogen receptors, ERa and ERb.
ERa notably is strongly expressed in 80% of breast can-
c e r s[ 3 ] .O n c ee s t r o g e ni sb o u n dt oE R a,t h er e c e p t o r
dimerizes and associates with chromatin. ERa homodi-
mers bind either directly to a DNA sequence motif, the
estrogen response element [4-6], or indirectly via tether-
ing to other transcription factors such as specificity pro-
tein 1 (Sp1) [7,8], activating protein 1 (AP-1) [9,10], or
nuclear factor kappa b (NF-B) [11].
17b-Estradiol (E2) is the most prevalent intracellular
estrogen. Tiled or cDNA microarrays have been abun-
dantly used for the global analysis of 17b-Estradiol (E2)
responsive genes. Several studies have profiled the tran-
scriptional response to E2 in cultured cells, particularly
MCF-7 cells, and have uncovered comprehensive fea-
tures of E2 regulated gene expression. At early time
points following E2 induction a greater proportion of
genes are up regulated, while at later time points more
genes are down regulated [12]. It has been hypothesized
that early ERa-mediated down regulation might be due
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regulated genes at later time points might depend on
the up regulation of the corepressor nuclear receptor
interacting protein 1 (NRIP1), which mediates the
repression of ERa target genes [5]. Interestingly, only
about 20% to 30% of the E2-regulated genes represent
direct targets [13], as defined by treatment with the pro-
tein translation inhibitor cyclohexamide.
There is considerable variation in the results generated
by different laboratories, even for the same cell type and
hormone treatment[14]. Estimations of the number of
E2-regulated genes range from ≈100 to ≈1500[14]. As
noted by Cheung et al., [15] the differences between stu-
dies can be due to the origin and growth conditions of
the cell lines, the length of hormone treatment, the
array platforms used, or the bioinformatics methods
used for data analysis.
Meta-analysis allows combining the results of several
studies, to provide a global picture, with statistical sup-
port, and hopefully better power and specificity than
each of the original studies. Several meta-analysis appli-
cations for microarrays have been proposed [16-18].
Two methods have been most frequently applied: one is
to combine p-values, and the other is to combine effect
sizes. Combining p-values has been very useful in
obtaining more accurate estimates of significance. Choi
et al [16]have shown that combining effect sizes can
take into account inter-study variation. Here we have
used the Rank product [19] method to detect differen-
tially expressed genes in response to E2 treatment in
MCF-7 cell lines, by integrating multiple array datasets
from two different platforms across laboratories. This
method detects genes that are consistently highly ranked
in several replicated experiments, independently of their
numerical intensities. It generates a single significance
measurement for each gene in the combined study.
Results
Data set selection and processing
Microarray Data was downloaded from GEO (http://
www.ncbi.nlm.nih.gov/geo/) [20]. Nine time course stu-
dies were used for the meta-analysis. Two common time
points among the different datasets were selected for
further analysis: 3 to 4 hours of treatment (early) and 24
hours of treatment (late). In total we had 4 datasets that
were used for the early time point, and 7 datasets that
were used for the late time point (tables 1 and 2).
Eight of the 9 studies were provided with data normal-
ized by the Robust Multi-Array Average (RMA)[21]
method, or the related Guanine Cytosine Robust Multi-
Array Analysis (GCRMA)[22] method. For one study
raw scaled signal count values were provided. Rank pro-
duct method does not require the recalculation of the
normalized expression values. Thus we use the data
processed according to what w a sc o n s i d e r e db e s tp r a c -
tice in each lab.
For the meta-analysis, the probesets found in common
across the Affymetrix U133 GeneChip family was used.
There are 22,277 common probesets between the two
U133a and U133 plus 2.0, which map to 13,186 genes.
Meta-Analysis of gene expression data
The Rank product method was chosen, as non-para-
metric analyses are more robust in general, which is an
important concern in comparing experiments done in
different laboratories. The Rank product method has
been shown to give good results on microarray data
[18]. Out of 22,277 probe sets, we identified 1206 at the
early time point and 4193 at the late time point, with a
false discovery rate (called percentage of false positive
predictions or pfp, see methods) ≤ 0.05. The high pro-
portion of genes with low p-values indicates that many
more genes are found to be differentially expressed than
expected by chance. By mapping the probe sets to
genes, we have identified 991 unique genes differentially
expressed at the early time point and 3234 unique genes
t h a ta r ed i f f e r e n t i a l l ye x p r e s s e da tt h el a t et i m ep o i n t .
All results are available in Additional File 1.
We compared the proportion of top genes identified
in individual datasets with the top genes from the meta-
analysis, using Correspondence At the Top (CAT) plots
Table 1 Studies used for meta-analysis
GEO accession Reference Early Late
GSE3834 [34] * *
GSE9936 [35] * *
GSE11324 [36] *
GSE5840 [37] *
GSE3529 [38] *
GSE4006 [36] *
GSE4025 [39] *
GSE6800 [37] *
GSE8597 [40] *
Table 2 Conditions of treatment and expression measure
of each study
GSE dataset E2 Normalization
GSE3529 10 nM RMAExpress
GSE3834 10 nM RMAExpress
GSE4006 10 nM GCRMA
GSE4025 10 nM GCRMA
GSE5840 10 nM Raw scaled signal count
GSE6800 1 nM RMA
GSE8597 25 nM RMA
GSE9936 6 nM RMA
GSE11324 100 nM RMA
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Page 2 of 14[17]. CAT plots quantify the consensus of two lists,
based on ranks. For example if two lists have 40 genes
out of the first 100 in common, the their consensus at
rank 100 will be 40%. In Figure 1 the CAT plots are
shown for the top 800 probes (400 up-regulated and
400-down regulated) at each time point. These plots
show that no single study determines or influences the
final meta-analysis gene list. Table 3 also shows that the
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Figure 1 CAT plots. Concordance at the top plots comparing ranked probe set lists from of early time point (3-4 hrs) (A), and for late time
point (24 hrs) (B).
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Page 3 of 14meta-analysis is able to identify more genes at the same
pfp level, demonstrating an increased statistical power.
Top Genes
T a b l e s4a n d5s h o wt h et o p1 0u n i q u eg e n e sf r o mt h e
meta-analysis for the early time point and their ranks in
the individual datasets. The tables also show the ranks
of the union of all top 10 genes from individual datasets
and meta-dataset, to illustrate the specificity of the
meta-analysis relative to individual experiments.
The top early genes from the meta-analysis include
many well known direct targets of ERa and ERb [3].
The most significant ones include TFF1, CCND1,
I G F B P 4 ,C 3 ,A D O R A 1 ,G R E B 1 ,a n dM Y C ,w h i c hh a v e
been shown by candidate gene analysis to be estrogen
regulated genes in breast cancer cell lines.
Moreover, the top genes from both the early and late
time points form highly connected networks (Figure 2).
These interactions show the functional relevance of our
results, and point to the importance of networks in
interpreting E2 signaling in MCF-7. We can already see
in these data important differences between the early
and late regulated genes, with the top early genes
involved in cellular growth and proliferation. The early
network notably shows up-regulation of the nuclear
repressor protein NRIP1/RIP140[5], which is then
involved in the down-regulation of cyclin G2 (CCNG2)
and of monocyte-to-macrophage differentiation-asso-
ciated protein (MMD) (Figure 2A). The late gene net-
work is centered on ERBB2, a member of the epidermal
growth factor (EGF) family of receptor tyrosine kinases,
and one of the major molecular prognostic and predic-
tive markers in breast cancer (Figure 2B). ERBB2 is
known for its role in cell proliferation, growth, and
apoptosis. This network also includes NF-kappaB, which
plays a key role in the aggressiveness of breast cancer
cells [23,24].
Pathway analysis: Early time point
We have found 20 biological networks with a significant
involvement of the genes differentially expressed at the
early time point. Figure 3 shows the top network, which
is consistent with the network found using the top 30
genes only: again, ERRB2 plays a central role. This net-
work is annotated “infection mechanism, cellular growth
and proliferation, genetic disorder”.T h ei n t e r f e r o ns i g -
naling pathway, which is involved in negative regulation
of cellular proliferation and induction of cellular apopto-
sis, is down regulated. Of note, IRF6 is suggested to reg-
ulate epithelial cell differentiation, and several IRF
family members are known to harbor tumor suppressive
functions. We find IRF members IR6 and IRF9 to be
down regulated in MCF-7, which adds more evidence to
the hypothesis that down-regulation of the interferon
Table 3 Average number of genes identified at different
pfp levels and integration driven discovery rate (IDD) in
meta-analysis(shown in parenthesis)
Pfp Value Early Single Early Meta Late Single Late Meta
0.00001 101 147(0.32) 680 1271(0.46)
0.0001 112 210(0.47) 979 1673(0.41)
0.001 234 350(0.33) 1795 2223(0.2)
0.005 470 521(0.10) 2834 2803
“Single” reports the union of all genes recovered by any single study at a
given pfp value.
Table 4 Comparison of top 10 early up regulated genes
Genes GSE11324 GSE3834 GSE5840 GSE9936 Meta
RET 4 6 19 17 1
GREB1 1 1 * 26 2
CXCL12 12 4 * 33 3
MYBL1 3 5 * 85 4
CA12 15 18 48 19 5
IGFBP4 42 * 30 7 6
PMAIP1 20 27 * 14 7
RAPGEFL1 163 * 1 * 8
WWC1 171 32 8 102 9
SGK3 2 19 * * 10
TUBB2B * * 3 * 13
STC2 10 * * 15 14
EGR3 143 2 * 215 15
NRIP1 9 * * 44 18
SGK1 5 * * 347 19
AREG 138 9 24 61 23
MYC 19 7 * 104 24
HSPB8 * 3 56 62 25
PGR 153 * 2 * 29
FADS1 * * * 5 30
IL17RB * * * 4 39
PLOD2 6 * * 131 40
AMD1 7 ***4 1
RASGRP1 11 10 * * 42
TNP2 * * 7 * 49
MYB 8 * * 181 57
HOXC4 * * * 9 65
CHST8 * * 6 128 91
SERPINB9 * * * 3 113
GP5 * * 10 * 123
FCGR2B * * 4 * 141
TGM2 * * 5 * 153
TFF1 313 * * 8 210
TFF2 * * 9 * 217
HOXC6 * * * 1 282
PLAC1 * * * 2 290
The column gene includes a union of top 10 regulated genes from individual
studies and meta-analysis. The ranks of these genes are indicated in the
individual study and in the meta analysis studies. The asterisk * indicates that
the gene was not included in the significant list (pfp ≤ 0.05).
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Page 4 of 14Table 5 Comparison of top 10 late down regulated genes
Gene M gse3529 gse3834 gse4006 gse4025 gse6800 gse8597 gse9936
IL17RB 1 * * 8 5 * 12 2
TFF1 2 * * 92 19 * 655 1
CDK1 3 * 59 28 13 * 57 5
MYBL1 4 1 6 31 174 * 1 162
CDC20 5 43 3 * 15 * 310 3
CXCL12 7 15 8 135 68 * 17 57
PBK 8 39 16 * 18 * 23 33
RAB31 9 29 * 14 4 * 93 25
KIF2C 10 * 63 * 7 * 226 4
PDZK1 419 2 25 57 * * 414 *
GREB1 19 3 1 1 194 1 62 323
EGR3 184 4 42 41 * 4 19 *
AREG * 5 7 38 * 21 46 719
NPY1R 57 6 * 13 * * 187 96
MSMB 1650 7 * * * * * *
RASGRP1 * 8 * * * * 1020 *
FABP5 * 9 * * * 23 98 *
CELSR2 136 10 33 89 * 26 313 402
DHRS2 294 * 2 21 * * 639 542
PTTG1 29 * 4 * 77 * 346 14
KIF20A 18 * 5 * 17 * 304 7
PLK1 74 * 9 * 45 * 389 44
CENPA 15 71 10 * 39 * 270 9
GJA1 * * * 2 * * * *
WISP2 549 * 67 3 * * 342 *
ASCL1 704 * * 4 * * * 400
OLFML3 65 * * 5 114 * * 29
EPB41L3 605 * * 6 * * * 357
PEG10 567 * * 7 * * * 505
PGR 628 * * 10 * * 94 *
PRIM1 12 * * * 1 * 56 15
SLC7A5 107 * * * 2 24 * 132
PLAC1 17 * * 132 3 * 13 53
TPD52L1 14 32 * 97 6 19 363 39
KIF4A 21 * * * 8 * 148 8
TPX2 36 * 40 * 10 * 244 34
SLC26A2 293 * 66 109 * 2 290 *
PRSS23 101 21 * 61 61 3 675 246
PTP4A1 709 * * * * 5 * 966
CA12 30 55 * 65 44 6 249 60
HSPB8 1739 40 32 * * 7 * *
TSKU * * * * * 9 * *
SGK3 93 22 * 23 * * 2 778
UGT2B15 112 * * 26 * * 3 227
TMPRSS3 220 16 * 56 * 22 4 *
PCP4 255 * * * * * 5 867
MCM10 92 41 * * 200 * 6 243
DSCC1 132 62 * * * * 7 453
EXO1 338 * * * * * 8 *
DTL 53 * * 79 261 * 9 95
CENPI 463 * * * * * 10 *
DLGAP5 25 * 17 * 54 * 159 10
The column gene includes a union of top 10 regulated genes from individual studies and meta-analysis. The ranks of these genes are indicated in the individual
study and in the meta analysis studies. The asterisk * indicates that the gene was not included in the significant list (pfp ≤ 0.05).
Jagannathan and Robinson-Rechavi BMC Systems Biology 2011, 5:138
http://www.biomedcentral.com/1752-0509/5/138
Page 5 of 142A
2B
Figure 2 Highly connected network of top 30 ranked genes at early time point (A). and late time point (B) as identified with IPA. Green
node color indicates down regulation and red node color indicates up regulation. White color indicates nodes that are not included in the
dataset but were assimilated into network by interaction with other molecules. Direct and indirect interactions between genes are denoted with
solid and dashed lines respectively. The style of the arrows indicates specific molecular relationships and the directionality of the interaction (A
acts on B). The shapes are indicative or the molecular class (i.e. protein family). Horizontal oval = transcription regulator, vertical diamond =
enzyme, and circle = other.
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3B
Figure 3 Top networks with IPA analysis at early time point (A). and late time point (B). Green node color indicates down regulation, and
red node color indicates up regulation. White color indicates nodes that are not included in the dataset but were assimilated into the network
by interaction with other molecules. Direct and indirect interactions between genes are denoted with solid and dashed lines respectively. The
style of the arrows indicates specific molecular relationships and the directionality of the interaction (A acts on B). The shapes are indicative or
the molecular class (i.e. protein family). Horizontal oval = transcription regulator, vertical diamond = enzyme and circle = other.
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Page 7 of 14signaling pathway might be important for uncontrolled
cellular proliferation[25].
The other top scoring networks at the early time point
contain genes involved in cell growth, proliferation,
DNA replication, protein amino acid metabolism, RNA
and protein trafficking, cellular movement, and lipid
metabolism. The merged image of the top three net-
works indicates three nodes centered on ERBB, cMYC
and FOS, all key regulators of proliferative responses
(see Additional File 2). In addition, several proteins
involved in protein translation and metabolism are up
regulated, including seven mitochondrial ribosomal
proteins.
In addition to searching for relations amongst the dif-
ferentially regulated genes, we can map them to very
well established ("canonical”) pathways. In this view, the
early genes appear involved in signaling pathways such
as wnt/b-catenin signaling, RAR activation and VDR
activation (Figure 4A).
Pathway analysis: Late time point
At the late time point the top network is annotated “cel-
lular assembly and organization, cell cycle, DNA replica-
tion, recombination and repair”. Figure 4 shows that the
ERBB2 network is now involved in interaction with
genes involved in cell division and cell cycle. The 5 top
scoring gene networks share several common genes
regulated at both time points, although they sometimes
change in opposite directions. This similarity between
time points indicates that most of the major gene
expression changes start to take place as early as 3 hrs.
This is clear comparing the early and late response of
the genes that are involved in molecular mechanisms of
cancer (Figure 5).
Genes that are down regulated at the late time point
also include a large proportion of structural and cell
adhesion genes, such as collagens, keratins, and other
intermediate filament proteins. Other down regulated
genes that are potentially involved in the development
of cancer include superoxide dismutase 3 (SOD3), cyclin
D2 (ccnd2), transthyretin (Ttr), bone morphogenetic
protein 2 (BMP2) and matrix metalloproteinase 2
(Mmp2).
Finally, the late genes can be mapped to canonical
pathways involved in breast cancer, and cell cycle and
division (Figure 4B).
Comparison with the GEMS dataset
A previous meta-analysis of E2 treated MCF cell lines
was done by Ochsner et al. [26]. They used a parametric
(weighted t-stats) method to obtain a gene expression
meta-signature (GEMS) for E2-regulated gene expres-
sion in MCF-7 cells. We compared the pathway analysis
for the top 50 down regulated and top 50 up regulated
genes of the early time point of each study (Figure 6).
Table 6 shows the list of central genes in each resulting
network. Curiously, the GEMS derived network for early
genes resembles more the networks derived from late
genes by the Rank product method. Notably, it is cen-
tered on ERBB2 and ERK. Another difference is that the
Rank product produces more highly connected genes
which have been shown in the literature to be regulated
by ERa, than GEMS. This includes ERa itself, which is
not a top gene in the GEMS analysis. Also notable is
the vascular endothelial growth factor (VEGF), which is
central in the network derived from Rank product, but
is not detected significantly in any individual study, nor
by the GEMS analysis. VEGF expression is strongly
induced as an immediate early response to E2 induction
in vivo (uterine epithelial cells), mediated by ERa and
hypoxia-inducible factor (HIF1a) [27].
Thus it seems that, while the GEMS analysis does
detect relevant E2 regulated genes, it provides a less
complete picture than the Rank product method does.
Discussion
We have identified 1206 probe sets and more than 10
pathways whose expression is significantly different
between control and E2 treated MCF-7 cells 3-4 hrs
after treatment, and 4193 probe sets and more than 20
pathways 24 hrs after treatment.
Although very little overlap exists on the gene level
between the nine expression profiling studies, the meta
analysis finds common functional processes and path-
ways. Table 3 shows that most of the genes identified in
individual studies were also identified in the meta-analy-
sis. The rank product algorithm returns a robust rank-
ing for all the top genes, leading to higher
reproducibility and increased specificity.
I ts h o u l db en o t e dt h a ta l lt h ed a t a s e t sw eu s e dw e r e
based on the Affymetrix platform. A recently available
dataset [28], using Illumina Beadchip, provides very
similar results to our analysis. Another very recent data-
set [29], using GRO-seq, although produced with a dif-
ferent focus on transient early response to E2, also
provides consistent results. Thus it does not seem that
our results are platform-dependent.
We have used pathway analysis tools to understand
the relationship between the regulated genes. Known
targets of ERa,s u c ha sM Y C ,E R B B 2 ,a n dE S R a,a r e
central genes at early and late time points. This shows
that the statistically significant genes are biologically
relevant, and that our analysis captures key aspects of
the underlying physiology.
Aryl hydrocarbon receptor (AhR) is a ligand activated
transcription factor involved in xenobiotic metabolism
and in mediating the toxic effects of dioxin-like com-
pounds. Crosstalk has been observed between AhR and
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Page 8 of 14ER, specifically with respect to ER signaling [30]. ERa
has been reported to have a positive role in AhR signal-
ing. We find this pathway highly regulated at both time
points.
The top canonical pathways regulated early are
involved in cellular growth, development and prolifera-
tion, whereas those regulated late are involved in DNA
replication, recombination and repair, cell cycle and cell
4A
4B
Figure 4 Top Canonical pathways regulated. (A) Early time point (B) Late time point. Green color denotes the percentage of genes in the
pathway that are down regulated and red color denotes the percentage of genes that are up regulated.
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5B.
Figure 5 Molecular mechanism of Cancer. (A) The genes regulated at the early time point. (B) The genes regulated at the late time point.
Green node color indicates down regulation, and red node color indicates up regulation. White color indicates nodes that are not included in
the dataset but were assimilated into network by interaction with other molecules. Direct and indirect interactions between genes are denoted
with solid and dashed lines respectively. The style of the arrows indicates specific molecular relationships and the directionality of the interaction
(A acts on B). The shapes are indicative or the molecular class (i.e. protein family). Horizontal oval = transcription regulator, vertical diamond =
enzyme and circle = other.
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Page 10 of 14death. These canonical pathways were not evident from
any of the individual studies. Another difference
between early and late response to E2 is early regulation
of transcription regulators, vs. late regulation of kinases
and transporters.
At the late time point we also see several genes com-
mon with the SV40T/t-antigen cancer signature identi-
fied by Deeb et al.[31] for human breast, prostate and
lung carcinomas. These include genes encoding 10 cen-
tromere proteins, 8 cyclins, 15 cell division cyle proteins,
6A.
6B.
Figure 6 Merged network created from the top 100 (50 down regulated and 50 upregulated) differentially expressed genes using (A)
Rank product algorithm, (B) the GEMS list.
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Page 11 of 147 kinesin-like family proteins, 7 multiple minichromo-
some maintenance-deficient proteins, and other prolif-
eration-related proteins and signal transduction proteins.
Conclusions
It is important to aggregate as much high-quality data as
possible to minimize sources of bias influencing gene
expression studies. The rank product methodology
favors genes that are consistently top ranked among
replicates. Therefore in the future other high quality
datasets can be integrated into this work, with minimum
effort. An interesting perspective will be to explore the
predictive power for clinical outcome [32] of breast can-
cer, of the gene set from meta-analysis, to the gene sets
from individual studies.
Methods
Meta-Analysis
The human genome U133A platform contain >22,000
probe sets and the human genome platform U133 Plus
2.0 array contains an additional >31,000 new probe sets,
giving a total of >54,000 probe sets. For the meta-analy-
sis, the probesets found in common across the Affyme-
trix U133 GeneChip family was used. There are 22,277
common probesets between the two U133a and U133
plus 2.0, that map to 13,186 genes.
The statistical significance of the results was evaluated
by the non-parametric algorithm ‘Rank products’ [33],
available as the ‘RankProd’ package at Bioconductor
(http://www.bioconductor.org) [19]. This method detects
genes that are consistently highly ranked in several
replicated experiments, independently of their numerical
intensities. This method ranks each feature within an
experiment based on that features’ score (e.g., Log
expression values), and then combines these ranks,
instead of combining the data or p-values. The results
are provided in the form of P values defined as the
probability that a given gene is ranked in the observed
position by chance. A list of differentially regulated
probe sets were selected based on the estimated percen-
tage of false positive predictions (pfp)[33], which is
equivalent to a false discovery rate. The pfp is calculated
using a permutation based procedure (100,000 permuta-
tions were conducted). Genes with a pfp of less than
0.05 were selected for further investigation. As the rank-
based procedure is non-parametric, it does not make
assumptions about the model and the parameters from
which the data came.
Evaluation of meta-analysis
We evaluated the performance of the Rank product
algorithm using Correspondence At the Top (CAT)
plots [17], which determine the proportion of genes in
common between experiments as a function of list size.
To generate CAT plots we use the lists of top genes for
each of the study including the meta studies and plot
proportion in common against the list size. We also
used integration-drive discovery (IDD) to measure the
number of extra genes identified by meta-analysis, com-
pared with the union set of all individual studies at the
same pfp threshold value.
Functional analysis
Functional classification analysis was done using the
Ingenuity Pathway Analysis software (version 8.5). The
“Core Analysis” was used, with a focus on canonical sig-
naling pathways. Core Analysis allows for a rapid assess-
ment and interpretation of large and small datasets in
the context of biological processes, pathways, and mole-
cular networks. In short, for a given function or path-
way, the statistical significance of pathway enrichment is
calculated using a right tailed Fisher’s exact test based
on the number of genes annotated, the number of genes
represented in the input dataset, and the total number
of genes being assessed in the experiment. A pathway
was deemed significant if the p-value of enrichment was
≤ 0.01. The p-value is adjusted for multiple comparisons
using FDR correction.
Additional material
Additional file 1: Results of the meta-analysis. Ranking of genes
following the meta-analysis, with meta-analysis scores and p-values.
Additional file 2: Supplementary Figure: merged networks for early
genes. Merged top three networks with IPA analysis at early time point.
Legend as Figure 3.
Abbreviations
ERα: Estrogen Receptor alpha; pfp: Percentage of False positive Predictions;
IPA: Ingenuity Pathway Analysis; CAT: Correspondence At the Top.
Table 6 Genes with most connections in networks from
figure 6 and their number of connections
Early probesets from
Rankproduct
Early Probeset from GEMS
Gene # of
Connections
Gene # of
Connections
MYC 31 ERBB2 25
FOS 29 ERK 21
BCL2L1 18 CXCL2 16
Mapk 15 NFkB complex 19
NFkB complex 16 Focal adhesion
kinase
11
PGR 11
Estrogen
Receptor
8
AP1 8
NR1P1 7
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